Germ Cell Tumors of the Gonads: A Selective Review Emphasizing Problems in Drug Resistance and Current Therapy Options
Mark Schrader(Arbeitsgemeinschaft Urologische Onkologie), Martin Schostak(Aturo), Carsten Stephan(Charité - Universitätsmedizin Berlin), Stefan Hinz(Charité - Universitätsmedizin Berlin), Klaus Jung(University of Veterinary Medicine Hannover, Foundation), Peter Albers(Düsseldorf University Hospital), Hans Krause(Charité - Universitätsmedizin Berlin), Frank Christoph(Charité - Universitätsmedizin Berlin), Michael Lein(Charité - Universitätsmedizin Berlin), Kurt Miller(Charité - Universitätsmedizin Berlin), Michael Hoepfner(Freie Universität Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin)
Cited by 14
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k